Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May 13:14:67-77.
doi: 10.2147/HMER.S365443. eCollection 2022.

Prevalence of HIV and Its Co-Infection with Hepatitis B/C Virus Among Chronic Liver Disease Patients in Ethiopia

Yayehyirad Tassachew  1   2   3 , Tamrat Abebe  1 , Yeshambel Belyhun  4 , Tezazu Teffera  5 , Abate Bane Shewaye  6   7 , Hailemichael Desalegn  8 , Henok Andualem  9 , Abiy Kinfu  10 , Andargachew Mulu  2 , Adane Mihret  1   2 , Rawleigh Howe  2 , Abraham Aseffa  2
Affiliations

Prevalence of HIV and Its Co-Infection with Hepatitis B/C Virus Among Chronic Liver Disease Patients in Ethiopia

Yayehyirad Tassachew et al. Hepat Med. .

Abstract

Background: The efficient use of antiretroviral drugs has significantly reduced AIDS-related morbidities and mortalities; however, mortality due to non-AIDS-related end-stage liver diseases is escalating in those living with HIV.

Objective: The study was designed to determine the prevalence of HIV and its co-infection with HBV and HCV among chronic liver disease (CLD) patients in Ethiopia.

Methods: Three hundred and forty-five CLD patients were included in this study in two groups: Hepatocellular carcinoma (HCC) (n=128) and non-HCC (n=217) patients. The non-HCC group comprised patients with advanced liver disease (n=98) and chronic hepatitis (n=119). Enzyme immunoassays were used to determine HBV and HCV infection markers. In addition, a serial rapid HIV testing algorithm was employed to screen HIV infection.

Results: Regardless of the stage of liver disease, the overall frequency of HIV was 4.3% (15/345), with a 2% (7/345) and 0.3% (1/345) of HIV/HBV and HIV/HCV co-infection rate. Of all HIV-infected patients (n=15), 46.7% (7/15) and 6.7% (1/15) were co-infected with HBV (HBsAg+HBcAb+) and HCV (anti-HCV+ HCV-RNA+), respectively, and 86.7% (13/15) exhibited a marker of HBV exposure (total HBcAb+). Overall, the frequency of HIV and its co-infection with HBV was more noticeable among HCC than non-HCC patients [8.6% (11/128) vs 1.8 (4/217), p=0.005 and 3.9% (5/128) vs 0.9% (2/217), p=0.1]. The rate of HIV mono-infection was 3.9% (5/128) vs 0.9% (2/217) among HCC and non-HCC patients.

Conclusion: The frequency of HIV and its co-infections with HBV/HCV exhibited an increasing pattern with the severity of the liver disease. Thus, screening all HIV-positive patients for HBV and HCV infection and all CLD patients for HIV infection and taking necessary preventive measures would be an essential strategy to prevent the progression of CLD and death related to liver disease in people living with HIV.

Keywords: HBV; HCC; HCV; HIV; non-AIDS liver diseases.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
Frequency of HIV and co-HIV/HBV and HIV/HCV infection according to the stage of liver disease.
Figure 2
Figure 2
Trend of HIV and co-HIV/HBV infection across the different age groups of chronic liver disease patients in Ethiopia.
See this image and copyright information in PMC

References

    1. Paik JM, Golabi P, Younossi Y, Mishra A, Younossi ZM. Changes in the global burden of chronic liver diseases from 2012 to 2017: the growing impact of NAFLD. Hepatology. 2020;72 (5):1605–1616. doi:10.1002/hep.31173 - DOI - PubMed
    1. UNAIDS. Global HIV & AIDS statistics – 2020 fact sheet. Available from: https://www.unaids.org/en/resources/fact-sheet. Accessed May 6, 2022.
    1. Jefferies M, Rauff B, Rashid H, Lam T, Rafiq S. Update on global epidemiology of viral hepatitis and preventive strategies. World J Clin Cases. 2018;6 (13):589. doi:10.12998/wjcc.v6.i13.589 - DOI - PMC - PubMed
    1. World Health Organization. Global hepatitis report 2017. World Health Organization; 2017.
    1. Thio CL, Seaberg EC, Skolasky JR, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). The Lancet. 2002;360 (9349):1921–1926. doi:10.1016/S0140-6736(02)11913-1 - DOI - PubMed